Who funds liver disease research?

We count 115 funded liver disease projects, active between 2022 and 2033, from 7 funders. The most came from EU · ERC (34 projects), EU · MSCA (21 projects) and EU · Health (18 projects). The median award is $2.6M, across the 110 of 115 projects that list an amount.

Funded projects

115

Funders

7

Median award

$2.6M

Open calls now

2

Top funders of liver disease research

Projects whose title or summary mentions liver disease. Median award: of the projects that list an amount, in US dollars; “—” when fewer than 3 do.

Open liver disease funding calls

2 open calls mention liver disease today.

• Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
  National Institutes of HealthNot specifiedDeadline: January 7, 2028 ·
  Real odds: About 1 in 8 funded (13% · NIH R01-equivalent grants, all NIH institutes, FY2025)
• Silvio O. Conte Digestive Diseases Research Core Centers (P30-Clinical Trial Optional)
  National Institutes of HealthUp to $750,000Deadline: February 10, 2027 ·

Real odds

• About 1 in 8 funded · 13% · NIH R01-equivalent grants, all NIH institutes, FY2025 · NIH Data Book, report 29

Published success rates for the programs behind the open calls above: the share of applications the funder funded, program-wide, not for this topic.

Funded liver disease projects

A sample, latest start first, at most three per program.

• MRC CoRE in Restorative Immunology
  UKRI · MRC · £21,647,682 · ends 2033
• Defining T and B-cell correlates of viral control for tissue-optimised, vaccine-guided immunotherapy
  Wellcome · £2,362,316 · ends 2032
• Center for Rational HCV Vaccine Design & Evaluation
  NIH · NIAID · $3,282,170 · ends 2031
• Patient-specific, combinatorial NAMs for gastrointestinal diseases and drug response prediction
  NIH · NCATS · $3,240,000 · ends 2030
• Examining pathways of PFAS exposure and their impacts on hyperlipidemia in a rural community impacted by land spreading
  NIH · NIEHS · $3,343,688 · ends 2030
• Induced pluripotent stem cell-derived endothelial cell therapy for liver disease
  NIH · NIDDK · $3,517,102 · ends 2030
• Hepatitis B and HIV Cure Consortium (BICC)
  NIH · NIAID · $4,640,294 · ends 2030
• Hepatotoxicity of Legacy and Replacement PFAS: Role of BRUCE-Mitochondrial Interactions
  NIH · NIEHS · $3,872,186 · ends 2030
• CELLULAR & EXTRACELLULAR ‘CONVERSATIONS’ IN CHRONIC LIVER DISEASE
  UKRI · UKRI FLF · £595,590 · ends 2029
• Novel macrophage mediated signals regulate the immunoregulatory environment of the neonatal liver
  NIH · NIDDK · $3,176,680 · ends 2029

How we count

Funded projects come from public award records (NIH RePORTER, NSF, EU CORDIS, UKRI Gateway to Research, Wellcome, the Gates Foundation, DOE, NASA and USDA NIFA) whose title or summary matches “liver”. NIH lists each budget year separately; one project counts once. Amounts are as the funder lists them; medians use only projects that list one, in US dollars. Open calls and forecasts are from our listings of October 28, 2026. A project can mention a topic without being mainly about it, so treat the counts as a guide to who funds the area.